Organisation paid for research Program year 2025 Source: CMS Open Payments

Cancer Specialists LLC

Neither a doctor nor a teaching hospital

Research payments

$3,732,133

561 payments

Through program year 2025, Cancer Specialists LLC is reported as receiving $3,732,133 in research payments, across 561 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,273,180 168
2024 Research $1,057,391 152
2023 Research $316,849 48
2022 Research $379,150 68
2021 Research $162,277 54
2020 Research $328,081 55
2019 Research $215,206 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $1,118,950 15 payments
  2. Genentech, Inc. $629,481 97 payments
  3. AbbVie, Inc. $547,046 79 payments
  4. Daiichi Sankyo Inc. $329,459 116 payments
  5. Janssen Research & Development, LLC $309,564 109 payments
  6. AstraZeneca Pharmaceuticals LP $164,079 17 payments
  7. EMD Serono, Inc. $153,321 33 payments
  8. Sanofi US Services Inc. $117,171 26 payments
  9. GlaxoSmithKline, LLC. $77,282 28 payments
  10. Celgene Corporation $69,451 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma $661,332 2 payments
  2. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) $256,675 37 payments
  3. A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma $241,708 25 payments
  4. Morningsun $222,056 37 payments
  5. Ds7300-127 $176,751 96 payments
  6. An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer $153,321 33 payments
  7. Ds8201-U-106 $138,134 14 payments
  8. a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 $132,525 1 payment
  9. MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $128,270 1 payment
  10. A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma $117,171 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record